US2020297822A1PendingUtilityA1

Methods, Compounds, and Compositions For Treatment and Prophylaxis in the Respiratory Tract

65
Assignee: ANSUN BIOPHARMA INCPriority: Nov 6, 2009Filed: Jun 4, 2020Published: Sep 24, 2020
Est. expiryNov 6, 2029(~3.3 yrs left)· nominal 20-yr term from priority
A61P 11/00A61P 35/00A61K 31/7016A61K 38/47A61K 33/14A61K 47/34A61K 47/22A61K 31/198A61K 47/32A61P 1/04A61K 45/06A61P 25/32A61K 9/06C12Y 302/01018A61K 9/0014A61K 31/4172C07K 2319/00A61P 37/04A61K 9/0073C12N 9/2402A61K 9/0043A61K 9/0053C12Q 1/34A61K 33/06G01N 2500/00A61P 31/18A61K 38/1808A61P 31/06C12N 9/2477G01N 2800/122A61K 47/26A61K 47/02A61K 9/0019C07K 14/485A61K 49/0008A61P 11/12A61K 31/05
65
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention provides a method of reducing the quantity of mucus in the respiratory tract of a subject with elevated levels of mucus in said respiratory tract. The method includes administering to the subject a compound or composition containing a therapeutically effective amount of a fusion protein comprising a sialidase or an active portion thereof and an anchoring domain. The therapeutically effective amount comprises an amount of the fusion protein that results in a reduction of the quantity of mucus in the respiratory tract after administration of the compound or composition when compared to the quantity of mucus present prior to administration of the compound or composition.

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
         1 . A method of reducing the quantity or level of mucus or preventing an increase in the quantity or level of mucus in a respiratory tract of a subject, the method comprising:
 administering to the subject a compound or composition comprising a therapeutically effective amount of a fusion protein, wherein   the fusion protein comprises at least one catalytic domain of a sialidase, wherein the catalytic domain of the sialidase comprises the sequence of amino acids extending from amino acid 274 to amino acid 666 of SEQ ID NO:12, inclusive, and at least one anchoring domain, wherein the anchoring domain is a glycosaminoglycan (GAG) binding domain of human amphiregulin comprising the amino acid sequence of SEQ ID NO:7; and   the therapeutically effective amount comprises an amount of the fusion protein that results in a reduction of the quantity of mucus in the respiratory tract after administration of the compound or composition when compared to the quantity of mucus present prior to administration of the compound or composition.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.